Business
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
CULVER CITY, Calif., February 17, 2026--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance hosted by the Ministry of Investment of Saudi Arabia (MISA). The engagement advanced two regulatory priorities:
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/8833549e55411ee5c62903f0f80d146c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FHYbp.29hng3EdTcETIvTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8833549e55411ee5c62903f0f80d146c","width":480,"height":270}},"lazy":false},{"type":"text","content":"Saudi FDA (SFDA) Encouraged Company to Submit Regulatory File for Recombinant BCG and Discussions Initiated for the Expansion of ANKTIVA® in Combination with Checkpoint Inhibitors Across Multiple Tumor Types in the Kingdom of Saudi Arabia (KSA)","length":244,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"ImmunityBio held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh convened under the Saudi-USA Biotech Alliance, hosted by the Ministry of Investment of Saudi Arabia (MISA)","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"SFDA encouraged the company to submit a regulatory package for ImmunityBio’s recombinant BCG (rBCG) to expand BCG access for Saudi Arabia to overcome the BCG shortage","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ImmunityBio and SFDA initiated discussion for expansion of ANKTIVA® (nogapendekin alfa inbakicept) plus checkpoint inhibitor (CPI) combination for additional tumor types beyond NSCLC, building on the accelerated approval granted in January 2026 for metastatic non-small cell lung cancer (NSCLC) in the CPI relapsed population","length":325,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The QUILT-3.055 basket trial has demonstrated that ANKTIVA rescues checkpoint inhibitor activity across multiple tumor types, including NSCLC, urothelial, head and neck, melanoma, renal, gastric, and cervical cancers, with a median overall survival of 14.1 months in CPI relapsed NSCLC patients","length":294,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"SFDA has now approved ANKTIVA across two indications in Saudi Arabia: BCG unresponsive non muscle invasive bladder cancer and metastatic NSCLC in combination with checkpoint inhibitors","length":184,"tagNa...